Guanhao Biotech(SZ:300238)2022-12-06 11:28Group 1: Company Overview and Technology - Crown Bio focuses on regenerative medicine, specifically in biological materials and regenerative medical devices, with a technology platform based on animal tissue [2][3] - The company has established a cell therapy technology platform since 2013, aiming to enhance resource integration and industrial transformation in the regenerative medicine field [3] Group 2: Market Potential and Product Details - The market for the "Youdeqing" corneal product is significant, with an estimated 4-5 million corneal blind patients in China, of which about half could potentially be treated with lamellar corneal transplantation [3][4] - Each year, over 100,000 new cases of corneal blindness arise, with an estimated 70% of these patients eligible for treatment through lamellar corneal transplantation [3] Group 3: Training and Sales Strategy - Training is required for doctors to perform lamellar corneal transplantation, with approximately 3,000 doctors in China qualified to perform cataract surgeries, half of whom use the company's products [4][5] - The company has shared marketing channels with Zhuhai Xiangle and has completed training for two batches of doctors to promote the "Youdeqing" product [4][5] Group 4: Product Performance and Market Share - The "Youdeqing" decellularized corneal implant has a clinical success rate (blindness recovery rate) of 83.3%, exceeding the clinical standard of 75% [4] - The hard dura mater patch has captured approximately 40% of the domestic market share, gradually replacing imported products due to its superior performance [5] Group 5: Research and Development Focus - The company is focusing on mature products nearing industrialization, with ongoing research in bone filling materials and medical PEEK materials [6] - The immune cell storage business, initiated in 2014, contributed only 0.9% to total revenue in 2015, but the company plans to expand into immune cell therapy as regulations and policies evolve [6] Group 6: Future Plans and Funding - The company’s incubator for life and health technology aims to attract global projects and support startups in the health sector [7] - The controlling shareholder plans to reduce holdings by 17.177 million shares, with funds allocated for industrial acquisitions and strategic partnerships to enhance competitiveness [7]